CSAG2 Antikörper

Produktnummer ABIN265187

Der Kaninchen Polyklonal Anti-CSAG2-Antikörper wurde für WB und EIA validiert. Er ist geeignet, CSAG2 in Proben von Human zu detektieren.

Kurzübersicht für CSAG2 Antikörper (ABIN265187)

Target: CSAG2 (CSAG Family, Member 2 (CSAG2))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CSAG2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-CSAG2 Antikörper

Spezifität: This antibody detects Trag 3. Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40).

Aufreinigung: Purified

Immunogen: Synthetic peptide derived from the human Trag-3 protein

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot: 0.5-2 μg/mLELISA.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store the product (in aliquots) at -20 °C. Can be shipped at 2 - 8 °C.

Details zu CSAG2

Target: CSAG2 (CSAG Family, Member 2 (CSAG2))

Andere Bezeichnung: CSAG2

Hintergrund: The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR(10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer. First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript.Synonyms: CT24.2, Cancer/testis antigen 24.2, Chondrosarcoma-associated gene 2/3 protein, TRAG-3, TRAG3, Taxol-resistant-associated gene 3 protein

Gen-ID: 389903

NCBI Accession: NP_001074317

UniProt: Q9Y5P2